The results of RT‒qPCR and western blot analyses showed that KRAS G12D inhibitor treatment significantly downregulated ZDHHC20 expression in pancreatic cancer cells (Figs. 2E and S4B). Here, KRAS is linked to pancreatic neoplasm.